Get the Stockscreener App
0.3791
1.46%
-0.0056
Pre-market:
.38
0.0009
+0.24%
Sangamo Therapeutics Inc stock is traded at $0.3791, with a volume of 4.53M.
It is down -1.46% in the last 24 hours and down -10.80% over the past month.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
See More
Previous Close:
$0.3847
Open:
$0.3852
24h Volume:
4.53M
Relative Volume:
0.78
Market Cap:
$127.57M
Revenue:
$52.29M
Net Income/Loss:
$-134.84M
P/E Ratio:
-0.5055
EPS:
-0.75
Net Cash Flow:
$-117.11M
1W Performance:
+3.58%
1M Performance:
-10.80%
6M Performance:
-35.26%
1Y Performance:
-66.45%
1-Day Range:
$0.3621
$0.3927
1-Week Range:
$0.3621
$0.41
52-Week Range:
$0.3621
$1.40
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
Name
Sangamo Therapeutics Inc
Sector
Industry
Phone
(510) 970-6000
Address
501 CANAL BLVD., RICHMOND, CA
Compare SGMO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGMO
Sangamo Therapeutics Inc
|
0.3791 | 129.45M | 52.29M | -134.84M | -117.11M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-07-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-13-24 | Upgrade | Truist | Hold → Buy |
| Dec-10-24 | Reiterated | H.C. Wainwright | Buy |
| Nov-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Apr-28-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-27-23 | Upgrade | Wedbush | Neutral → Outperform |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-13-22 | Resumed | Wedbush | Neutral |
| May-04-21 | Initiated | RBC Capital Mkts | Outperform |
| Jan-07-21 | Resumed | Guggenheim | Neutral |
| Jan-06-21 | Initiated | Stifel | Hold |
| Dec-16-20 | Resumed | H.C. Wainwright | Buy |
| Sep-08-20 | Initiated | BofA Securities | Buy |
| Jul-07-20 | Initiated | SunTrust | Buy |
| Aug-26-19 | Initiated | H.C. Wainwright | Buy |
| Nov-14-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-09-18 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-10-18 | Initiated | Guggenheim | Buy |
| Jun-20-18 | Initiated | BofA/Merrill | Buy |
| Nov-15-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Nov-01-16 | Downgrade | Wedbush | Outperform → Neutral |
| Oct-19-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Dec-04-15 | Initiated | Wells Fargo | Outperform |
| Oct-23-15 | Resumed | Jefferies | Buy |
| May-03-13 | Initiated | BioLogic Equity Research | Sell |
| Feb-23-11 | Reiterated | JMP Securities | Mkt Outperform |
| Jul-29-10 | Reiterated | Wedbush | Outperform |
| Oct-19-09 | Initiated | Brean Murray | Sell |
| Oct-07-09 | Reiterated | Leerink Swann | Outperform |
| Aug-25-09 | Reiterated | JMP Securities | Mkt Outperform |
View All
Sangamo Therapeutics Inc Stock (SGMO) Latest News
Dow Update: Is Sangamo Therapeutics Inc a strong growth stock2025 Market WrapUp & Long Hold Capital Preservation Tips - baoquankhu1.vn
How The Pulled Price Target Is Reshaping The Story For Sangamo Therapeutics (SGMO) - Yahoo Finance
Genome Editing Market Forecast to Reach $23.6 Billion by 2031 Registering 16.6% CAGR: Insights Into Technology and Investment Trends - GlobeNewswire Inc.
Aug Selloffs: Does Sangamo Therapeutics Inc have a sustainable dividendWeekly Stock Analysis & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Insider Sell: Whats the outlook for FRSXs sectorWeekly Market Summary & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Analysts Expect Breakeven For Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Before Long - simplywall.st
Does Sangamo Therapeutics Inc. have pricing powerEntry Point & Low Drawdown Momentum Trade Ideas - bollywoodhelpline.com
Published on: 2026-01-14 05:13:16 - Bộ Nội Vụ
Fabry Disease Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, AVROBIO, 4D Molecular Therapeutics - Barchart.com
Sangamo Therapeutics (SGMO) Shares Stabilize Amid Recent Key Pipeline Update - Finviz
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Can Sangamo Therapeutics Inc. stock attract ESG capital inflowsEarnings Growth Report & High Accuracy Buy Signal Tips - Улправда
Is Sangamo Therapeutics Inc. stock oversold or undervaluedWeekly Trend Recap & Daily Growth Stock Investment Tips - Улправда
Why Sangamo Therapeutics Inc. stock remains resilient2025 Momentum Check & Community Shared Stock Ideas - Улправда
Can Sangamo Therapeutics Inc. stock weather global recessionOptions Play & Long-Term Growth Portfolio Plans - Улправда
Surprises Report: How Sangamo Therapeutics Inc. stock compares to industry benchmarksJuly 2025 Technicals & Consistent Profit Trade Alerts - ulpravda.ru
Is Sangamo Therapeutics Inc. stock a contrarian buyMarket Trend Review & Long-Term Growth Stock Strategies - Улправда
Can Sangamo Therapeutics Inc. stock sustain market leadership2025 Volume Leaders & AI Optimized Trade Strategies - Улправда
Inflation Data: How Sangamo Therapeutics Inc. stock compares to industry benchmarks2025 Dividend Review & High Win Rate Trade Tips - Улправда
How Sangamo Therapeutics Inc. stock performs in weak economy2025 Risk Factors & Weekly High Momentum Picks - ulpravda.ru
How resilient is Sangamo Therapeutics Inc. stock in market downturnsJuly 2025 WrapUp & Low Drawdown Trading Techniques - Улправда
Will Sangamo Therapeutics Inc. (GBY) stock benefit from infrastructure billMarket Weekly Review & AI Forecast Swing Trade Picks - Улправда
Is Sangamo Therapeutics Inc. stock attractive for retirement portfoliosFootwear buying guidance for outdoor walking and light jogging focuses on support for wide feet, making it a smart choice when deciding what to buy. - ulpravda.ru
Will Sangamo Therapeutics Inc. stock reach Wall Street targets2026 world cup usa national team final top scorers possession football expert forecast preview - Улправда
Sangamo Therapeutics (HAM:GBY) 9-Day RSI : 29.67 (As of Jan. 05, 2026) - GuruFocus
Q3 2025 Sangamo Therapeutics Inc Earnings Call Transcript - GuruFocus
Sangamo Therapeutics Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript - GuruFocus
Sangamo Therapeutics (HAM:GBY) Preferred Stock - GuruFocus
Sangamo Therapeutics Inc (HAM:GBY) DCF Valuation - GuruFocus
Sangamo Therapeutics Inc Stock Baskets - GuruFocus
Sangamo Therapeutics (HAM:GBY) Intrinsic Value: Projected F - GuruFocus
Sangamo rises after trial data for Fabry disease therapy - MSN
H.C. Wainwright Maintains Buy Rating on Sangamo Therapeutics (SGMO) - MSN
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates - sharewise.com
Sangamo Therapeutics Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
Why Sangamo Therapeutics Inc. stock could outperform in 2025Oil Prices & High Return Trade Guides - Улправда
Revenue Check: Can Sangamo Therapeutics Inc. stock surprise with earnings upsideJobs Report & Expert Approved Momentum Ideas - moha.gov.vn
Sangamo Starts Putting BLA for Fabry Disease Gene Therapy Isa-Vec in Front of FDA - CGTLive®
Growth Value: How Sangamo Therapeutics Inc. stock trades before earningsJuly 2025 PostEarnings & High Conviction Buy Zone Alerts - Улправда
How Sangamo Therapeutics Inc. stock trades before earningsJuly 2025 Gainers & Weekly Consistent Profit Watchlists - Улправда
Sangamo initiates rolling BLA submission for Fabry disease gene therapy By Investing.com - Investing.com Nigeria
Sangamo Therapeutics initiates rolling submission of BLA to U.S. FDA - marketscreener.com
Sangamo (SGMO) Begins BLA Submission for Promising Fabry Disease Therapy - GuruFocus
Sangamo initiates rolling BLA submission for Fabry disease gene therapy - Investing.com India
Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease - The Manila Times
Single-dose gene therapy for rare Fabry disease moves toward FDA review - Stock Titan
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Average Rating of "Hold" by Analysts - MarketBeat
Sangamo Therapeutics Earnings Notes - Trefis
Sangamo reports positive Fabry disease gene therapy results - MSN
How the Narrative Surrounding Sangamo Therapeutics Is Shifting After New Regulatory and Valuation Signals - Yahoo Finance
Book value per share of Sangamo Therapeutics, Inc. – SWB:GBY - TradingView — Track All Markets
Sangamo Therapeutics Inc Stock (SGMO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.09%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):